Yesterday during President Donald Trump's first cabinet meeting, Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. mistakenly said two people died in a Texas measles outbreak, but dismissed the news, saying measles outbreaks happen every year in the United States. 

In other measles news, Kentucky has reported a case in an adult who had recently traveled internationally. 

Kennedy gets death count wrong

During the cabinet meeting, Kennedy said, "There have been four measles outbreaks this year. In this country last year there were 16. So, it's not unusual. We have measles outbreaks every year." 

He did not provide context on the size of the outbreaks. The current outbreak in rural West Texas has at least 124 cases, almost all in unvaccinated children, many of whom are connected to a Mennonite community. The entire country for all of 2024 saw 285 confirmed cases, but we're not even one sixth of the way into 2025.

Kennedy also said two people have died, but Texas officials yesterday confirmed only one death, in an unvaccinated child hospitalized in Lubbock. The last pediatric measles death in the United States before this was in 2003. An adult woman also died from measles in 2015. 

The HHS Secretary said kids were being hospitalized for quarantine purposes during the Texas outbreak. But yesterday hospital officials from Covenant Children's Hospital in Lubbock clarified that 20 kids are hospitalized for issues such as breathing problems, and not quarantine. 

Kentucky resident visited gym while infectious

Yesterday the Kentucky Department for Public Health (KDPH) and Franklin County Health Department announced a confirmed case of measles identified in an adult Kentucky resident. It said citizens may have been exposed to the person at a Planet Fitness gym in Frankfort in mid-February.

"The resident attended a fitness center in Frankfort, Kentucky, while infectious," the KDPH said in a statement. 

The patient had recently traveled internationally to an area with ongoing measles transmission, the KDPH said. 

A retrospective study of patients with carbapenem non-susceptible infections and limited treatment options at 24 US hospitals found that imipenem/cilastatin/relebactam (IMI/REL) was effective and well-tolerated, researchers reported yesterday in Open Forum Infectious Diseases.

IMI/REL is a beta-lactam/beta-lactamase inhibitor combination that was approved by the Food and Drug Administration (FDA) in 2019 for treating complicated infections caused by multidrug-resistant (MDR) gram-negative pathogens. While FDA approval was based on data from randomized controlled trials that showed IMI/REL was efficacious, well-tolerated, and noninferior to comparator antibiotics, the type of patients who have MDR gram-negative infections typically aren't eligible for such trials. 

The aim of the study, which was led by researchers at Wayne State University, was to assess the performance of IMI/REL in real-world settings. The primary outcome was clinical success, defined as improvement or resolution of infection-related signs/symptoms while receiving IMI/REL.

Clinical success in 70% of patients

A total of 151 patients (median age, 60; 54.3% male) received IMI/REL for 48 hours. The most common source of infection was the lower respiratory tract, which accounted for 52.3% of cases. Most patients (85.4%) had a carbapenem non-susceptible organism, and 72.2% received IMI/REL for targeted treatment of Pseudomonas aeruginosa. There was a high burden of comorbid conditions among the patients, including diabetes (39.1%), heart failure (28.5%), and chronic kidney disease (25.8%).

Clinical success was achieved in 70.2% of patients, and adverse events occurred in 6%, with three instances of IMI/REL discontinuation. Multivariable analysis found that heart failure, receipt of antibiotics within the past 90 days, intensive care unit admission at time of index culture collection, and isolation of difficult-to-treat P aeruginosa were independently associated with reduced odds of clinical success.

The study authors say the findings offer valuable insights into the demographics and clinical characteristics of patients prescribed IMI/REL.

"Our findings highlight the potential of IMI/REL as a valuable therapeutic option in challenging clinical scenarios," they wrote. "Continued investigation into its application among specific situations, including comparative analyses, will be important to more completely understand its place in therapy to combat the escalating threat of MDR Gram-negative infections."